Evidence map›Paper›PMID 32458097›Full record

ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2020

HIF-1α, HIF-2α, and ProExC: diagnostic or prognostic relevance in conjunctival intraepithelial neoplasia?

Simone Nuessle, Daniel Soriano, Daniel Boehringer, Hans Mittelviefhaus, Clemens Lange, Thomas Reinhard, Lisa Atzrodt, Claudia Auw-Haedrich

Open access · hybridAbstract read
In one paragraph

Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Expression of thrombospondin-1 in conjunctival squamous cell carcinoma is correlated to the Ki67 index and associated with progression-free survival.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Simone NuessleEye Center, Medical Center, Faculty of Medicine, University of Freiburg, Killianstr. 5, 79106, Freiburg im Breisgau, Germany. simone.nuessle@uniklinik-freiburg.de.ORCID http://orcid.org/0000-0003-4401-8344
Daniel SorianoEye Center, Medical Center, Faculty of Medicine, University of Freiburg, Killianstr. 5, 79106, Freiburg im Breisgau, Germany.
Daniel BoehringerEye Center, Medical Center, Faculty of Medicine, University of Freiburg, Killianstr. 5, 79106, Freiburg im Breisgau, Germany.
Hans MittelviefhausEye Center, Medical Center, Faculty of Medicine, University of Freiburg, Killianstr. 5, 79106, Freiburg im Breisgau, Germany.
Clemens LangeEye Center, Medical Center, Faculty of Medicine, University of Freiburg, Killianstr. 5, 79106, Freiburg im Breisgau, Germany.
Thomas ReinhardEye Center, Medical Center, Faculty of Medicine, University of Freiburg, Killianstr. 5, 79106, Freiburg im Breisgau, Germany.
Lisa AtzrodtEye Center, Medical Center, Faculty of Medicine, University of Freiburg, Killianstr. 5, 79106, Freiburg im Breisgau, Germany.
Claudia Auw-HaedrichEye Center, Medical Center, Faculty of Medicine, University of Freiburg, Killianstr. 5, 79106, Freiburg im Breisgau, Germany.
University of Freiburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe aim of this study was to investigate HIF-1α, HIF-2α, and ProExC expression in conjunctival intraepithelial neoplasia (CIN), to differentiate between metaplasia and dysplasia, and to access their value as diagnostic and prognostic immunohistochemical markers. Recurrence and progression into SCC (squamous cell carcinoma) were defined as endpoints.

methodsForty-three specimens including CIN I (2), CIN II (9), CIN III (29), with and without metaplasia, and metaplasia alone (3), as well as 21 conjunctival control specimens, were stained with antibodies against HIF-1α, HIF-2α, and ProExC. The percentage of positively stained cells were calculated and used for further analysis.

resultsThe mean percentages of HIF-1α and HIF-2α were not increased in CIN. In comparison, the expressions of these markers were even significantly elevated in control specimens (p < 0.001). Upper epithelial cells in CIN were more often ProExC-positive compared with normal conjunctiva or metaplasia (p = 0.06 and p = 0.07). Cox proportional-hazards analysis was performed for characterization of factors influencing the combined endpoint and showed a significant elevated hazard ratio for staining with ProExC (p = 0.04) compared with HIF-1α (p = 0.26) and HIF-2α (p = 0.49).

conclusionOur study shows that HIF-1α and HIF-2α do not serve as diagnostic or prognostic markers in CIN. ProExC seems to be a potential indicator for CIN, but not a reliable diagnostic marker. However, control specimens occasionally also display a high percentage of ProExC-positive cells and staining over the entire epithelial layer.

Indexed as

AdultAgedAged, 80 and overBasic Helix-Loop-Helix ProteinsBiomarkers, TumorCarcinoma, Squamous CellConjunctival NeoplasmsEndothelial PAS Domain-Containing Protein 1FemaleFollow-Up StudiesHumansHypoxia-Inducible Factor 1, alpha SubunitImmunohistochemistryMaleMiddle AgedPrognosisBasic Helix-Loop-Helix ProteinsBiomarkers, TumorEndothelial PAS Domain-Containing Protein 1Hypoxia-Inducible Factor 1, alpha SubunitConjunctival intraepithelial neoplasiaHIFimmunohistochemistryProExC

Identifiers

PMID32458097
PMCPMC7438294
OpenAlexW3030765228

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.